Correction notice of palisade bio's press release announcing the appointment of clinical advisory board members

Carlsbad, ca, feb. 08, 2024 (globe newswire) -- palisade bio, inc.   (nasdaq: pali) (“palisade” or the “company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (gi) diseases, today announced a correction to its press release originally issued on february 8, 2024, announcing the appointments of bruce sands, md, ms and florian rieder, md to its clinical advisory board (cab).
PALI Ratings Summary
PALI Quant Ranking